Gene therapy for lysosomal storage disorders

Area of Science:

• Biochemistry
• Genetics
• Cell Biology

Background:

• Lysosomal storage disorders (LSDs) are inherited metabolic diseases with diverse clinical features.
• Current therapies like bone marrow transplantation and enzyme replacement therapy have limitations, including poor efficacy for neurological symptoms and lack of lifelong cure.
• Gene therapy is emerging as a viable alternative for treating LSDs.

Purpose of the Study:

• To review gene therapy strategies for lysosomal storage disorders.
• To discuss the development and application of gene therapy for both neurological and non-neurological LSDs.
• To highlight preclinical studies supporting gene therapy for Gaucher disease Type I.

Main Methods:

• Review of existing literature on gene therapy for LSDs.
• Analysis of ex vivo and in vivo gene therapy approaches.
• Examination of viral vector technologies, including oncoretroviral, adeno-associated viral (AAV), and lentiviral vectors.

Main Results:

• Preclinical studies demonstrate the potential of gene therapy in addressing LSDs.
• Successful development of bone marrow transplantation and enzyme replacement therapy for some LSDs, but with significant limitations.
• Gene therapy strategies show promise, with some success in preclinical models.

Conclusions:

• Gene therapy represents a significant advancement for treating lysosomal storage disorders.
• Further research and clinical trials are warranted to optimize gene therapy for LSDs.
• Gene therapy holds potential for a more effective and potentially curative treatment for LSDs, especially for neurological manifestations.